These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22733158)

  • 1. AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.
    Bolam KA; Galvão DA; Spry N; Newton RU; Taaffe DR
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):329-38. PubMed ID: 22733158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
    Owen PJ; Daly RM; Livingston PM; Fraser SF
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
    Ott C; Fulton MK
    J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study.
    Bourke L; Doll H; Crank H; Daley A; Rosario D; Saxton JM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):647-57. PubMed ID: 21335510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Turner D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(2):198-203. PubMed ID: 18852703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
    J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.